Similar articles

• Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

  Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr. Levy R, et al. J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5. J Clin Oncol. 2014. PMID: 24799467 Free PMC article. Clinical Trial.
• Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.

  Schumacher K. Schumacher K. J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2(Suppl 2):R10-3. doi: 10.1007/BF01470993. J Cancer Res Clin Oncol. 2001. PMID: 11768618 Free PMC article. No abstract available.
• Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.

  Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Freedman A, et al. J Clin Oncol. 2009 Jun 20;27(18):3036-43. doi: 10.1200/JCO.2008.19.8903. Epub 2009 May 4. J Clin Oncol. 2009. PMID: 19414675 Free PMC article. Clinical Trial.
• BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.

  Flowers CR. Flowers CR. Expert Rev Vaccines. 2007 Jun;6(3):307-17. doi: 10.1586/14760584.6.3.307. Expert Rev Vaccines. 2007. PMID: 17542746 Review.
• BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.

  Reinis M. Reinis M. Curr Opin Mol Ther. 2008 Oct;10(5):526-34. Curr Opin Mol Ther. 2008. PMID: 18830928 Review.